NASDAQ: IAMIambic Therapeutics Inc Stock
$23.81+4.90 (+25.91%)
Updated Oct 16, 2026
IAM Price
$23.81
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$16.15
52 Week High
$25.00
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.33
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IAM Overview
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IAM's potential to beat the market
- IAM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IAM
RankedUnranked of 455
RankedUnranked of 455
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.83 | A | |
| $121.84 | A | |
| $9.98 | A |
Be the first to know about important IAM news, forecast changes, insider trades & much more!
IAM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IAM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IAM's short-term assets ($223.40M) exceed its short-term liabilities ($48.64M)
Short-term Liabilities Financials
IAM's short-term assets ($223.40M) exceed its long-term liabilities ($27.08M)
Long-term Liabilities Financials
IAM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more IAM due diligence checks available for Premium users.
Valuation
IAM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$237.2M
Liabilities
$75.7M
Debt to equity
-0.33
IAM's short-term assets ($223.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IAM's short-term assets ($223.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IAM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IAM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Iambic Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.